Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04542252
Other study ID # BCV-HV01
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date November 9, 2020
Est. completion date January 29, 2021

Study information

Verified date April 2021
Source SymBio Pharmaceuticals
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To evaluate the effect of coadministered cyclosporine on the pharmacokinetics of brincidofovir following simultaneous administration of SyB V-1901 with cyclosporine, or coadministration of cyclosporine at 2 hours after the completion of SyB V-1901 infusion in healthy adult subjects


Description:

This study is an open-label, randomized and crossover study designed to evaluate the effect of cyclosporine on the pharmacokinetics of SyB V-1901. Healthy adult subjects will receive an IV dose of SyB V-1901 alone, simultaneous administration of SyB V-1901 with cyclosporine, and coadministration of cyclosporine at 2 hours after completion of SyB V-1901 infusion. Eligible subjects will be randomized to one of two groups, to receive the treatment sequence of assigned group.


Recruitment information / eligibility

Status Completed
Enrollment 13
Est. completion date January 29, 2021
Est. primary completion date December 22, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 20 Years to 55 Years
Eligibility Main Inclusion Criteria: - Healthy adult male aged between 20 to 55 years at informed consent - BMI from 18 to 32 kg/m2 with a body weight of = 50 kg - Creatinine Clearance = 60 mL/min at screening - Judged to be in good general health, based on the review of medical history and the screening and Pre-Day1 examination Main Exclusion Criteria: - Positive for HIV antibody, or HBs antigen, or HCV antibody at the screening or within 6 months prior to the start of screening - Have a history of infection of SARS-CoV-2, or subjects who have close contact with infected patients of SARS-CoV-2 within 2 weeks prior to screening or visit to epidemic area of SARS-CoV-2 infection in outside of Japan or have close contact with person who visit to epidemic area of SARS-CoV-2 infection within 2 weeks prior to screening - Positive for SARS-CoV-2 polymerase chain reaction (PCR) in lower respiratory tract specimens, nasopharyngeal swabs or saliva and so on at screening or have a fever = 37.5 °C and respiratory symptoms - Have a history of drug abuse or alcohol dependence within 2 years prior to the start of screening - Have a history of gastrointestinal disorders or cholecystectomy etc., which could interfere with the absorption of cyclosporine or could interfere with normal gastrointestinal anatomy or motility, but except for uncomplicated appendectomy. - Have a history or symptoms of cardiovascular disease, including but not limited to coronary artery disease, hypertension, congestive heart disease, and clinically significant cardiac disorder. - Have a history of hematological disorders or have a risk of gastrointestinal bleeding - Have a history of chronic liver disease or hepatic impairment, including but not limited to alcoholic liver disease, chronic viral hepatitis, autoimmune hepatitis, steatosis or hemochromatosis. - Have increased Alanine aminotransferase (ALT) or Aspartate aminotransferase (AST) greater than ULN at screening or Pre-Day1 - History of Gilbert's syndrome or increased total bilirubin greater than 1.5x the upper limit of the normal range at screening or Pre-Day1 - Have symptoms of infection within 2 weeks prior to Pre-Day1 - Have clinically significant abnormal hemoglobin at the screening or Pre-Day1, or a clinically significant iron deficiency - Have a history of blood donation or had clinically significant blood loss within 30 days prior to Day 1, or platelet/plasma donation within 7 days prior to Day 1 - Have received any investigational drug, or device within 30 days prior to Day1 - History of tobacco- or nicotine-containing product use within 6 months prior to Day1

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
SyB V-1901
SyB V-1901 10 mg via IV infusion for 2 hours
Cyclosporine
200 mg Capsule

Locations

Country Name City State
Japan Research Site Hachioji-shi Tokyo

Sponsors (1)

Lead Sponsor Collaborator
SymBio Pharmaceuticals

Country where clinical trial is conducted

Japan, 

Outcome

Type Measure Description Time frame Safety issue
Other Genotype of CYP4F2 Pre-Day1
Other Genotype of OATP1B1 Pre-Day1
Primary Maximum Plasma Concentration (Cmax) of brincidofovir (BCV) From initiation of SyB V-1901 administration though 16 days
Primary Area under the plasma concentration versus time curve (AUC) of BCV From initiation of SyB V-1901 administration though 16 days
Secondary Cmax of cidofovir (CDV) From initiation of SyB V-1901 administration though 16 days
Secondary AUC of CDV From initiation of SyB V-1901 administration though 16 days
Secondary Cmax of Intercellular Cidofovir diphosphate (CDV-PP) in Peripheral Blood Mononuclear Cells (PBMCs) From initiation of SyB V-1901 administration though 18 days
Secondary AUC of Intercellular CDV-PP in PBMCs From initiation of SyB V-1901 administration though 18 days
Secondary Cmax of cyclosporine in blood From initiation of cyclosporine administration though 16 days
Secondary AUC of cyclosporine in blood From initiation of cyclosporine administration though 16 days
Secondary Number of subjects with adverse events (AE) Follow up 22 days post dose
Secondary Number of subjects with severity of AEs Follow up 22 days post dose
Secondary Number of subjects with abnormal findings for laboratory parameters Follow up 22 days post dose
Secondary Number of subjects with abnormal findings for blood pressure Follow up 22 days post dose
Secondary Number of subjects with abnormal findings for respiratory rate Follow up 22 days post dose
Secondary Number of subjects with abnormal findings for heart rate Follow up 22 days post dose
Secondary Number of subjects with abnormal findings for temperature Follow up 22 days post dose
See also
  Status Clinical Trial Phase
Completed NCT05574374 - Drug-drug Interactions Between DWP14012 and DWC202202 in Healthy Subjects Phase 1
Completed NCT04557397 - Fruquintinib CYP3A Inhibitor and Inducer Study Phase 1
Completed NCT06031454 - Drug-durg Interaction of Leritrelvir(RAY1216) With Midazolam, Omeprazole, Rosuvastatin, Verapamil, and Rifampin Phase 1
Completed NCT05137600 - A Drug-Drug Interaction Study Between ATI-2173 and Midazolam or Clarithromycin in Healthy Subjects Phase 1
Recruiting NCT06119958 - Drug-drug Interactions Between DWC202313 and DWC202314 in Healthy Subjects Phase 1
Active, not recruiting NCT05812404 - Phase 1 Clinical Trial to Evaluate the Effect of DWP14012 on the Pharmacokinetics of DWC202201 in Healthy Subjects Phase 1
Completed NCT04606537 - Drug to Drug Interaction Study of KBP-5074 in Healthy Subjects Phase 1
Completed NCT04939467 - Dedicated Drug-Drug Interaction (DDI) Study in Healthy Volunteers Phase 1
Enrolling by invitation NCT06037564 - B-free Multistage Trial Phase 4
Completed NCT05123820 - Pharmacokinetics of Omeprazole and Midazolam When Co-administered With ACT-1014-6470 Phase 1
Recruiting NCT04840862 - Impact of Rifabutin on the Pharmacokinetics of Elexacaftor/Tezacaftor/Ivacaftor Phase 4
Completed NCT04814498 - Drug-Drug Interaction (DDI) Study in Healthy Volunteers Phase 1
Completed NCT01350921 - Evaluation of the Drug-drug Interaction Between Ticagrelor and Venlafaxine When Taken Together in Healthy Volunteers Phase 1
Completed NCT03103568 - A Study to Investigate the Potential Influence of Nitisinone on the Metabolism and the Transport of Other Drugs in Healthy Volunteers Phase 1
Completed NCT04840641 - Flucloxacillin as an Inducer of CYP-enzymes Phase 1
Completed NCT05860114 - Givinostat and Metabolites Pharmacokinetics in Urine and Plasma (Part 3) Phase 1
Completed NCT05845567 - The Potential of Givinostat as DDI Victim in Co-administration P-gp Inhibitor (Part 2) Phase 1
Completed NCT05304845 - Drug-drug Interactions Between DWP14012 and Aspirin in Healthy Subjects Phase 1
Completed NCT04776499 - Possible Effects of Propylthiouracil, Riociguat and Perphenazine on Circulation of Healthy Volunteers Phase 1
Completed NCT03909529 - Drug-drug Interaction (DDI) Study of Spironolactone (Perpetrator) and Digoxin (Substrate Drug) Phase 1